 |
 |

Association Between HTLV-III/ LAV Infection and Tuberculosis in Zaire
Jonathan Mann, MD, MPH;
Dixie E. Snider, Jr, MD, MPH;
Henry Francis, MD;
Thomas C. Quinn, MD;
Robert L. Colebunders, MD;
Peter Piot, MD;
James W. Curran, MD, MPH;
Nzila Nzilambi, MD;
Ngaly Bosenge, MD;
Matiatudila Malonga, MD, MPH;
Dikilu Kalunga, MD;
Masaki Mu Nzingg, MD;
Nkoko Bagala, MD
JAMA. 1986;256(3):346.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
 |
 |
To the Editor.—
Immunosuppression caused by drugs, infections, cancer, or other conditions is known to increase the risk of tuberculosis.1 Studies of patients with the acquired immunodeficiency syndrome (AIDS)2,3 and of the incidence of tuberculosis in young men in selected US cities4 suggest that an increased risk of overt disease among persons previously infected with the tubercle bacillus may be associated with human T-cell lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) infection.
Project SIDA is a collaborative AIDS research project in Zaire, involving the Zairian Department of Public Health, the Public Health Service, and the Institute of Tropical Medicine, Antwerp, Belgium. In March 1985, project researchers determined the prevalence of antibody to HTLV-III/LAV in 231 (84%) of the 274 inpatients of the tuberculosis sanatorium in Kinshasa, Zaire.
Of the 231 study participants, 159 (69% ) had confirmed pulmonary tuberculosis (positive results of sputum examination for acid-fast bacilli). Of these
. . . [Full Text PDF of this Article]
Footnotes
Edited by Drummond Rennie, MD, Senior Contributing Editor; Sharon Iverson, Assistant Editor.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|